Pulmatrix, Inc. Stock

PULM

US74584P3010

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-27 EDT			5-day change	1st Jan Change
1.490 ^USD	+3.47%		+4.20%	-33.18%

08-13	Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Analysts' recommendations: Pulmatrix, Inc.

22-03-30	HC Wainwright Adjusts Pulmatrix's Price Target to $10 from $5, Keeps Buy Rating	MT
21-04-13	Pulmatrix : HC Wainwright Adjusts Pulmatrix' Price Target to $5 From $10, Keeps Buy Rating	MT

More recommendations

Press Releases: Pulmatrix, Inc.

09-22	Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria	AQ
08-13	Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger	PR
05-15	Pulmatrix Announces First Quarter 2026 Financial Results	PR
04-21	Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger	PR
04-13	PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders	BU

More press releases

Managers and Directors: Pulmatrix, Inc.

Manager	Title	Age	Since
Peter Ludlum CEO	Chief Executive Officer	70	2024-07-19

Director	Title	Age	Since
Richard Batycky BRD	Director/Board Member	58	2019-10-31
Christopher Cabell BRD	Director/Board Member	57	2020-06-22
Todd Bazemore BRD	Director/Board Member	55	2020-09-30

More insiders

Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Companyâ€™s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrixâ€™s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-27	US$1.490	+3.47%	68,380
26-10-26	US$1.440	-2.70%	6,398
26-10-23	US$1.480	+4.23%	9,031
26-10-22	US$1.420	-9.55%	27,720
26-10-21	US$1.570	+9.79%	130,744

Delayed Quote Nasdaq

More quotes

Market Cap	5.44M 4.88M 4.51M 4.09M 7.64M 517M 7.74M 54.07M 21.47M 271M 20.43M 19.99M 859M	P/E 2024	-2.67x	P/E 2025	-1.58x
Enterprise Value	1.35M 1.22M 1.12M 1.02M 1.9M 129M 1.92M 13.45M 5.34M 67.41M 5.08M 4.97M 214M	EV / Sales 2024	2.05x	EV / Sales 2025	-
Free-Float	99.22%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq	PULM	Delayed
CBOE	PULM	Real-time
Deutsche Boerse AG	2PU	Delayed
Börse Stuttgart	2PU	Delayed
Tradegate	2PU	Real-time
Boerse Muenchen	2PU	Real-time

08-13	Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-21	Pulmatrix, Inc. announced that it has received $1 million in funding	CI
04-21	Pulmatrix announces closing of preferred stock transaction as part of planned merger	RE
03-26	Eos SENOLYTIX, Inc. entered into an Agreement and Plan of Merger and Reorganization to acquire Pulmatrix, Inc. in a reverse merger transaction.	CI
03-25	Pulmatrix, Inc. announced that it expects to receive $1 million in funding	CI
03-02	Pulmatrix announces termination of prior planned merger and continues pursuit of alternative merger opportunities	RE
02-27	Cullgen Inc. cancelled the acquisition of Pulmatrix, Inc. in a reverse merger transaction.	CI
02-26	Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-18	Pulmatrix and Cullgen continue to pursue merger	RE
25-10-16	Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-16	Biopharma Pulmatrix's Q3 revenue drops to $0 as trial ends, plans asset divestment	RE
25-08-06	Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

1 day	+3.47%
1 week	+4.20%
Current month	-1.97%
1 month	-7.45%
3 months	-13.87%
6 months	+12.03%
Current year	-33.18%

1 week	1.39	1.56
1 month	1.34	1.63
Current year	1.16	3.4
1 year	1.16	4.99
3 years	1.16	10.4
5 years	1.16	19.53
10 years	1.16	1,396

Pulmatrix, Inc. Stock

Stocks

PULM

US74584P3010

Biotechnology & Medical Research

Valuation: Pulmatrix, Inc.

Chart: Pulmatrix, Inc.

Latest news: Pulmatrix, Inc.

Analysts' recommendations: Pulmatrix, Inc.

Press Releases: Pulmatrix, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Pulmatrix, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/26/23	Michael Higgins	Free	Chairman	2,436	0.0669%
1/26/23	Christopher Cabell	Free	Director	1,700	0.0467%
1/26/23	Richard Batycky	Free	Director	1,700	0.0467%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PULMATRIX, INC.	+3.47%	+4.20%	-69.78%	-20.32%	5.26M
WUXI APPTEC CO., LTD.	-3.10%	-4.19%	+32.67%	+59.47%	65.28B
ARGENX SE	+0.33%	+0.33%	+10.16%	+78.07%	54.57B
LONZA GROUP AG	+0.16%	+1.73%	+9.89%	+102.10%	53.59B
IQVIA HOLDINGS INC.	-0.75%	+1.38%	+24.89%	+50.91%	45.03B
BEONE MEDICINES AG	-1.30%	-4.80%	+16.05%	+114.76%	42.17B
REVOLUTION MEDICINES, INC.	+1.26%	-5.26%	+221.12%	+900.64%	39.42B
CELLTRION, INC.	-0.74%	-4.46%	+11.00%	+44.65%	32.71B
WUXI BIOLOGICS (CAYMAN) INC.	+2.15%	-7.77%	+23.94%	-9.78%	24.01B
GENMAB A/S	+1.11%	+15.18%	+60.27%	+49.33%	26.5B
Average	+0.25%	+0.27%	+34.02%	+136.98%	38.33B
Weighted average by Cap.	-0.42%	-0.59%	+42.43%	+153.36%

	2024	2025
Net sales	7.81M 7.01M 6.47M 5.87M 10.96M 741M 11.1M 77.56M 30.8M 389M 29.3M 28.67M 1.23B	-
Net income	-9.56M -8.58M -7.92M -7.18M -13.43M -908M -13.59M -94.97M -37.72M -476M -35.88M -35.11M -1.51B	-5.16M -4.63M -4.28M -3.88M -7.25M -490M -7.34M -51.29M -20.37M -257M -19.38M -18.96M -815M
Net Debt	-9.52M -8.55M -7.89M -7.15M -13.37M -904M -13.54M -94.6M -37.57M -474M -35.74M -34.97M -1.5B	-4.09M -3.67M -3.39M -3.07M -5.74M -388M -5.81M -40.62M -16.13M -204M -15.35M -15.02M -645M